Phase transfer catalyzed asymmetric alkylations of imine glycinamides

Tetrahedron Asymmetry

Volumn 14, Issue 17, 2003, Pages 2539-2545

  Kumar, Sanjeev ^a   Ramachandran, Uma ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO N 1 (2,6 DIMETHYLPHENYL) N 2 (DIPHENYLMETHYLENE)NORLEUCINAMIDE; GLYCINAMIDE; IMIDE; LEVOBUPIVACAINE; N (2,6 DIMETHYLPHENYL) N (DIPHENYLMETHYLENE)PHENYLALANINAMIDE; N (DIPHENYLMETHYLENE) 1 OXO 3 PHENYL 1 PIPERIDIN 1 YLPROPAN 2 AMINE; N (DIPHENYLMETHYLENE) 1 OXO 3 PHENYL 1 PYRROLIDIN 1 YLPROPAN 2 AMINE; N (DIPHENYLMETHYLENE) 2 OXO 2 PIPERIDIN 1 YLETHANAMINE; N (DIPHENYLMETHYLENE) 2 OXO 2 PYRROLIDIN 1 YLETHANAMINE; N (TERT BUTYL) N (DIPHENYLMETHYLENE)PHENYLALANINAMIDE; N 1 (2,6 DIMETHYLPHENYL) N 2 (DIPHENYLMETHYLENE)GLYCINAMIDE; N 2 (DIPHENYLMETHYLENE) N 1 ISOPROPYLGLYCINAMIDE; N 2 (DIPHENYLMETHYLENE) N 1,N 1 DICYCLOHEXYLGLYCINAMIDE; N 2 (DIPHENYLMETHYLENE) N 1,N 1 DIETHYLGLYCINAMIDE; N ISOPROPYL N (DIPHENYLMETHYLENE)PHENYLALANINAMIDE; N,N DICYCLOHEXYL N (DIPHENYLMETHYLENE)PHENYLALANINAMIDE; N,N DIETHYL N (DIPHENYLMETHYLENE)PHENYLALANINAMIDE; TERT BUTYL 6 CHLORO N (DIPHENYLMETHYLENE)NORLEUCINATE; TERT BUTYL N (DIPHENYLMETHYLENE)PHENYLALANINATE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CATALYSIS; CHEMICAL MODIFICATION; CHIRALITY; DRUG SYNTHESIS; ENANTIOSELECTIVITY; PHASE TRANSITION; PRIORITY JOURNAL;

EID: 0041830967     PISSN: 09574166     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-4166(03)00441-5     Document Type: Article

References (36)

1. O'Donnell M.J., Bennett W.D., Wu S. J. Am. Chem. Soc. 111:1989;2353-2355.
2. O'Donnell M.J., Wu S. Tetrahedron: Asymmetry. 3:1994;591-594.
3. Lygo B., Wainwright P.G. Tetrahedron Lett. 38:1997;8595-8598.
4. Lygo B., Crosby J., Peterson A.J. Tetrahedron Lett. 40:1999;8671-8674.
5. Lygo B., Crosby J., Peterson A.J. Tetrahedron Lett. 40:1999;1385-1388.
6. Lygo B. Tetrahedron Lett. 40:1999;1389-1392.
7. Lygo B., Humphreys D.L. Tetrahedron Lett. 43:2002;6677-6679.
8. Corey E.J., Xu F., Noe M.C. J. Am. Chem. Soc. 119:1997;12414-12415.
9. Jew S.-s., Yoo S.-M., Jeong S.-B., Park Y., Park H.-g. Org. Lett. 4:2002;4245-4249.
10. Ooi T., Kameda M., Maruoka K. J. Am. Chem. Soc. 121:1999;6519-6520.
11. Ooi T., Takeuchi M., Kameda M., Maruoka K. J. Am. Chem. Soc. 122:2000;5228-5229.
12. Ooi T., Kameda M., Tannai H., Maruoka K. Tetrahedron Lett. 41:2000;8339-8342.
13. Ooi T., Uematsu Y., Kameda M., Maruoka K. Angew. Chem., Int. Ed. 41:2002;1551.
14. Ooi T., Kameda M., Maruoka K. J. Am. Chem. Soc. 125:2003;5139-5151.
15. Ooi T., Tayama E., Maruoka K. Angew. Chem., Int. Ed. 42:2003;579-582.
16. Oppolzer W., Moretti R., Thomi S. Tetrahedron Lett. 30:1989;6009-6010.
17. Lopez A., Pleixats R. Tetrahedron: Asymmetry. 9:1998;1967-1977.
18. Liu W.-Q., Roques B.P., Garbay C. Tetrahedron Lett. 38:1997;1389-1392.
19. Deng P.-W., Wong A.K., Kirk L.K. Tetrahedron: Asymmetry. 13:2002;1135-1140.
20. Guillena G., Najera C. Tetrahedron: Asymmetry. 9:1998;1125-1129.
21. Guillena G., Najera C. Tetrahedron: Asymmetry. 9:1998;3935-3938.
22. Guillena G., Najera C. J. Org. Chem. 65:2000;7310-7322.
23. Ikemani S., Hayama T., Katsuki T., Yamaguchi M. Tetrahedron Lett. 27:1986;3403-3406.
24. Ikemani S., Uchiyama S., Hayama T., Katsuki T., Yamaguchi M. Tetrahedron. 44:1998;5333-5342.
25. Kanemasa S., Mori T., Tatsukawa A. Tetrahedron Lett. 34:1993;8293-8296.
26. Gristwood R., Baker H., Dickens J. Expert Opin. Invest. Drugs. 11:1994;1209.
27. Federsel H., Jaksch P., Sandberg R. Acta Chem. Scand. B41:1987;757-761.
28. Tullar B.F. J. Med. Chem. 14:1971;891-893.
29. Adger B., Dyer U., Hutton G., Woods M. Tetrahedron Lett. 37:1996;6399-6402. and references cited therein.
30. Corey E.J., Noe M.C., Xu F. Tetrahedron Lett. 39:1998;5347-5350.
31. Leeuwen S.H.v., Quaedflieg P.J.L.M., Broxterman Q.B., Liskamp R.M.J. Tetrahedron Lett. 43:2002;9203-9207.
32. Weiberth F.J., Hall S.S. J. Org. Chem. 52:1987;3901-3904.
33. O'Donnell M.J., Polt R.L. J. Org. Chem. 47:1982;2663-2666.
34. The O-benzyl-N-anthracenemethylcinchonidium bromide was minimized using Tripos force field for 500 cycles. The Powell method was used for minimization. The charges were calculated by Gasteiger Huckel charges. Similarly the enolate was minimized using Tripos, Powell method. Energy difference 0.001 was used as the convergence criteria.
35. Lipkowitz B.K., Cavanaugh W.M., Baker B., O'Donnell M.J. J. Org. Chem. 56:1991;5181-5192.
36. Lygo B., Crosby J., Lowdon T.R., Wainwright P.G. Tetrahedron. 57:2001;2391-2402.